chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I noticed that my endurance was diminished for two weeks and when I when I went to the hospital on 07/06/2021. I was diagnosed with multiple bilateral Pulmonary Emboli confirmed by ultrasound. I also had a DVT in my right leg slightly to the medial side of my knee. It was treated with anticoagulants. Currently I have no symptoms.
6 x 2 cm redness at injection site of Prevnar 10 days after immuniz tender to touch. Appears to be muscular Rx only. Tx Cool compress and Motrin.
Hair is falling out; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 75-year-old female patient received BNT162b2 (BNT162B2), on 27Mar2021 as dose 1, single (Lot number: ER8730, Expiration Date: 31Mar2021) at the age of 75 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "blood pressure" (unspecified if ongoing). The patient took concomitant medications. The following information was reported: ALOPECIA (non-serious), outcome "not recovered", described as "Hair is falling out".  Additional information: The patient did not had any other conditions, investigations and other products. The patient had all of the shots and everything, even the last one she had. Since she started getting vaccines the patient had noticed her hair was falling out. She started to do research and back tracking everything and noticed it was the vaccine. The patient wanted to know if anything she can do to prevent losing all her hair. The patient always had thick hair and now all of a sudden it was extremely thin. Several months later noticed hair was falling out, like noticed it 6 to 8 months after getting the vaccine. Her drain was full of hair and never had that. Had not talked to her doctor about it yet. The patient was given a blood pressure medicine around this time by her doctor. The patient thought at first it was the blood pressure medicine. However, she stopped the medicine and her hair would continue to fall out and she realized it was not the blood pressure medicine. She confirmed she does not remember the name of the blood pressure medicine. The adverse event did not resulted in Physician Office or Emergency Room visit. The patient did not undergo any relevant lab tests. When probed for details started as, probably when she was 75 or 76. It had been going on however long she had been getting the vaccine.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201239009 Same patient/AE/drug, different dose of vaccine;US-PFIZER INC-202201239010 Same patient/AE/drug, different dose of vaccine;US-PFIZER INC-202201236667 Same patient/AE/drug, different dose of vaccine;US-PFIZER INC-202201239008 Same patient/drug, different AE, different dose of vaccine;
No additional AEs; Administered an expired dose of ROTATEQ; This spontaneous report was received from a medical assistance referring to a patient of unknown age and gender. The patient's relevant medical history, drug reactions or allergies, and concomitant medications were not provided.      On 04-JAN-2022, the patient was vaccinated with expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 2 milliliter (expired product administered) (lot number T033510, expiration date 28-DEC-2021; dose number, vaccination scheme, route of administration, and anatomical location of vaccination were not reported) for prophylaxis.    No product quality complaints reported and no additional adverse events (no adverse event) were reported.
This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Caller stated her patient missed his second dose and wants to get it today which is after 35 day mark/he was supposed to get his second dose on 6May2021 but missed) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination. No Medical History information was reported. On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Caller stated her patient missed his second dose and wants to get it today which is after 35 day mark/he was supposed to get his second dose on 6May2021 but missed). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Caller stated her patient missed his second dose and wants to get it today which is after 35 day mark/he was supposed to get his second dose on 6May2021 but missed) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant medications were provided by reporter. No treatment medications were provided by reporter. Most recent FOLLOW-UP information incorporated above includes: On 01-Jul-2021: Follow-up information received on 01-JUN-2021 contains No Significant Information. On 01-Jul-2021: Follow-up information received on 01-JUN-2021 contains No Significant Information.
Initial report received on 6/9/06 from a health care professional. A 29 year old male patient with an allergy to chickens, but who is able to eat eggs had received a dose of YF-Vax, lot number UE804AA, in the right arm on 6/9/06 at 12:30 PM. The route of administration was not provided. 120 minutes later, at 14:30 PM, the patient developed mild shortness of breath, swelling in his throat, pink blotchy areas on his skin (unsure if this was normal skin coloration or from the vaccine), nausea with vomiting five times, and retching dry heaves. His vital signs were within normal limits. Per the reporter, the patient required medical evaluation. At the time of this report, the patient had not recovered from these adverse events. (OMIC)
Information has been received from a health professional concerning approximately ten females who were vaccinated with Gardasil vaccine. Subsequently, the patients experienced redness, swelling, pain and tenderness at the injection site. The nurse says the symptoms are more severe with dose 2 but occur sometimes after dose 1. Patients receive the vaccination from their primary physicians and usually come the next day to see her with the symptoms. She tells the patients to use an ice pack and assumes they all recover because none of them have returned. The patients are pre-teens (usually 12 years of age). Additional information has been requested. This is in follow-up to report (s) previously submitted on 12/14/2007. Information has been received from a health professional concerning an 11 year old female who was vaccinated with the first dose of GARDASIL vaccine on 13-NOV-2007. Subsequently the patient experienced redness, swelling, pain, and tenderness at the injection site. The patient complained of pain of 5/10 on the pain scale. The patient recovered from the symptoms.
DID NOT COMPLETE VIVOTIF ONE WEEK PRIOR TO TRAVEL; This spontaneous case report was received from a pharmacist (PVX2019-009) on 02-Jan-2019 and a follow-up was received on 04-Jan-2019. The report describes an adult female consumer who "did not complete Vivotif one week prior to travel". The consumer was receiving Vivotif (one dose every other day) for an unknown indication.  It was reported that the consumer took the first dose of Vivotif on 02-Jan-2019 and left to travel on Thursday (03-Jan-2019).   The action taken with Vivotif with respect to the event "did not complete Vivotif one week prior to travel" was not applicable.  The clinical outcome of the event "did not complete Vivotif one week prior to travel" was unknown.  Company's Comment: The causality of the event "did not complete Vivotif one week prior to travel" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "did not complete Vivotif one week prior to travel" was considered as not applicable.
ADMINISTRATION ERROR/INCORRECTLY STORED VACCINE ADMINISTERED; VACCINE STORED OUTSIDE OF THE ACCEPTABLE LIMITS; TEMPERATURE EXCURSION; This spontaneous report received from a physician concerned multiple patients.  No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1822811, and expiry: 20-MAR-2022) dose was not reported, administered on 18-OCT-2021 for prophylactic vaccination. No concomitant medications were reported. On 18-OCT-2021, the patient experienced administration error/incorrectly stored vaccine administered. On 18-OCT-2021, the patient experienced vaccine stored outside of the acceptable limits. On 18-OCT-2021, the patient experienced temperature excursion. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the administration error/incorrectly stored vaccine administered, temperature excursion, and vaccine stored outside of the acceptable limits was not reported. This report was non-serious.
Fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.            Concomitant medications were not reported  No treatment information was specified
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2016, a health care provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Information has been received from a medical assistant concerning three patients of unknown age and gender. The patients' medical history, concurrent conditions, concomitant medications and drug reactions/allergies were not provided. On unknown dates, the patients were vaccinated with doses of VARIVAX (lot #: M028553 with expiration date: 07-JUN-2018) (dose, strength, frequency, route of administration and anatomical location were not reported), for prophylaxis. The administered vaccines were improperly stored at temperature less than -14°C but greater than -10°C for 7 hours (digital data logger) without any previous temperature excursion. No adverse symptoms were reported. This is one of two reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1703USA009360.
This was the second covid dose for the patient.  There were no complications with the first dose.  Approximately 10-15 minutes after receiving the vaccination the child reported feeling tightness in her chest from her arm to her chest and felt like her heart was racing.  The child did appear nervous getting the vaccine.  She was given a bottle of water and we continued to monitor the child.  She still wasn't feeling good.  We took her blood pressure which was normal.  Mom wanted the paramedics called so she could be checked out.  The paramedics came and checked her vitals which appeared within normal range, however, she was transported to the hospital for further observation.
Patient was to receive the bivalent booster but received  the original primary series. no side effects were reported
This spontaneous report as received from a pharmacist refers to a patient of unknown age. On 06-MAR-2013, the patient was vaccinated with an expired 0.65 ml dose of ZOSTAVAX (Lot # 672428/1599AA, expiration date 13-JAN-2013) SQ. The patient was not experiencing any known symptoms. Additional information has been requested.
pt recv vax & devel a severe rash on the face & facial swelling;pt also exp pruritus & erythema @ the inj site;addtl info recv 4MAR96 indicated pt had recovered;
weakness; sick; sore throat; fever; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (weakness), ILLNESS (sick), OROPHARYNGEAL PAIN (sore throat) and PYREXIA (fever) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036B21A and 047A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Apr-2021, the patient experienced ASTHENIA (weakness), ILLNESS (sick), OROPHARYNGEAL PAIN (sore throat) and PYREXIA (fever). On 16-Apr-2021, ILLNESS (sick), OROPHARYNGEAL PAIN (sore throat) and PYREXIA (fever) had resolved. At the time of the report, ASTHENIA (weakness) outcome was unknown.            No Concomitant medications were reported.  No Treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 24-Jul-2021: Follow-up received: events were updated On 26-Aug-2021: Follow-up information included no new information.
Information has been received from a physician concerning an approximately 67 year old female patient. The patient had fair skin which was freckled. The patient had no known drug reactions or allergies. Concomitant therapies included amlodipine, clonidine, PRINIVIL, hydrochlorothiazide (manufacturer unknown), metformin, simvastatin (manufacturer unknown) and PROZAC. On an unspecified date in 2013, the patient received a 0.65 ml dose of ZOSTAVAX (lot number/expire date unspecified) subcutaneously at an unspecified pharmacy. Shortly after receiving ZOSTAVAX, on an unknown date the patient developed a lesion at the injection site that would not heal. On an unspecified date in June 2014, the patient had the area biopsied which revealed basal cell carcinoma in situ. On an unspecified date, the patient returned to the office to have the area resected. The outcome of the event was reported as recovered on an unknown date. The relationship between the event and ZOSTAVAX was not reported. Upon internal review, basal cell carcinoma was considered to be medical significant. Additional information has been requested.
This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (vaccine that underwent temperature excursions, administered to patient), POOR QUALITY PRODUCT ADMINISTERED (vaccine that underwent temperature excursions, administered to patient) and NO ADVERSE EVENT (No adverse event) in a 26-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 prophylaxis.     It was unknown if patient had ever been diagnosed or tested positive for COVID-19.     On 17-Sep-2022 at 2:50 PM, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 17-Sep-2022 at 2:50 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (vaccine that underwent temperature excursions, administered to patient). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (vaccine that underwent temperature excursions, administered to patient) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (vaccine that underwent temperature excursions, administered to patient), POOR QUALITY PRODUCT ADMINISTERED (vaccine that underwent temperature excursions, administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.         No concomitant product reported by the reporter. Patient received 0.5 (units unspecified) of Bivalent vaccine in deltoid. Patient had received previous 3 doses of vaccine, intramuscular with anatomical site as deltoid.  It was reported that refrigeration excursions identified, state vaccine was housed in the units. There were excursions noted. The Nurse called for a clinic that she was assisting. The clinic had a similar issue with vaccines stored in their freezer. Vaccines stored in the refrigerator that underwent several temperature excursions going back to August 2022. No adverse reactions reported to their knowledge for the patient. No treatment medication reported by the reporter.
MMRV given instead of Varicella. no reported adverse reaction. provider notified, no new orders received.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 07-MAY-2014 the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB (lot # J006245, expiration date 03-FEB-2016). This specified lot number vaccine was exposed to temperature excursion four times. The total cumulative excursion time of the first time was 32 hours with the lowest recorded temperature of 31 Fahrenheit degree. The total cumulative excursion time of the second time was 152 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the third time was 584 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the fourth time was 288 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Around 1:30am 2/5/2021 I started feeling feverish, chills, slight headache, body and muscle aches, slightly increased heart rate. I took my temperature with a digital forehead thermometer and no increase in temperature was noted. This could be a false reading given my symptoms. I took Tylenol around 10pm the evening before to prevent possible fever and aches. Now around 8:20am I still have described above symptoms. I?m continuing to rest and drink plenty of water.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA ACUTE RESPIRATORY FAILURE ACUTE HYPERCAPNIC RESPIRATORY FAILURE HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPERCAPNIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 7/31/2022 -- RECURRENCE OF SAME SYMPTOMS
Patient reported local site irritation (rash, swelling, hot to touch) and fever, chills and stomachache.
Fever of 103.0; Vomiting; Chills; weakness; shortness of breath; intense headache; lingering headache; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 10Apr2021 at 11:15 (at the age of 27-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medication included escitalopram (MANUFACTURER UNKNOWN) for an unknown indication from unknown date. The past drug history was reported as latex and peanuts. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 20Mar2021, as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 05:00, the patient experienced fever of 103.0, vomiting, chills, weakness, shortness of breath, intense headache and had lingering headache for a week after. The patient underwent lab tests and procedures which included body temperature on 11Apr2021 and resulted as 103.0 (units unspecified).  The clinical outcome of the events fever, vomiting, chills, weakness, shortness of breath and headache were recovered with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
I started to begin feeling tingling sensation in both muscles and joints around 3:00PM (~6.5 hrs post-vaccination). Upon returning home after 6pm, I began experiencing fever and chills. By this time, the joint pain had worsened and I was experiencing bouts/waves of chills with chest pain and shortness of breath. I then experienced extreme sensations of nausea with a compounded headache centralized to the occipital lobe region which lasted throughout the night and into the next day. I had vomited 7 times during the evening due to nausea and had difficulty trying to rest. I have not experienced anything like this before.
This spontaneous report as received from a medical assistant refers to a 4 years old child of unknown gender. The patient's medical history, concurrent conditions, drug allergies and concomitant medications were not reported. On 01-AUG-2017 the patient received a concomitant administration of VARIVAX (lot # M038858, Expiry date: 14-SEP-2018) and PROQUAD (lot # N009773, Expiry date : 28-SEP-2018) reconstituted with STERILE WATER DILUENT (unknown lot, unknown expiration) (overdose). No adverse effects reported. The outcome of overdose was unknown.
Body aches, low grade fever, headache, lymph node under arm swollen. Has seen improvement in those symptoms, but now has SOB and Sore throat, will be seeking testing.
HEADACHE, ON LEFT SIDE OF FACE, TEETH ACHE, NOSE ACHE, EAR ACHE BODY ACHE/SENSITIVITY  I THOUGHT THE FIRST SHOT WAS SINUS OR ALLERGIES- LASTED ABOUT A WEEK  2ND SHOT SAME SYMPTONS- PLUS FEVER OF 100.4
Left arm numbness and tingling that patient reports started the morning after she received the vaccine. Provider evaluated 10/11/2022 and believes likely relate to yesterday's vaccination. Possible pressure/immune phenomenon/?parsonage turner syndrome. Anticipate self limited nature of symptoms and patient advised if not improved to notify our office for further evaluation.